The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB 2 receptors

British Journal of Pharmacology

Volumn 150, Issue 6, 2007, Pages 693-701

  Guindon, J ^a   Desroches, J ^a   Beaulieu, P ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

2 arachidonoyl glycerol; Cannabinoid receptors; Endocannabinoids; Formalin test; Inflammatory pain; Monoacylglycerol lipase; URB602

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; FORMALDEHYDE; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; URB 602;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; INFLAMMATION; MALE; MONOTHERAPY; NOCICEPTION; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; RAT;

ANALGESICS, NON-NARCOTIC; ANIMALS; ARACHIDONIC ACIDS; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCERIDES; INDOLES; MALE; MONOACYLGLYCEROL LIPASES; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 33947302244     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706990     Document Type: Article

References (69)

1. Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V et al. (2000). Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396: 85-92.
2. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM et al. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106: 133-145.
3. 2 receptor. Eur J Pharmacol 396: 141-149.
4. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
5. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260.
6. Coderre TJ, Vaccarino AL, Melzack R (1990). Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res 535: 155-158.
7. De Léan A, Munson PJ, Rodbard D (1978). Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102.
8. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L (1998). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331: 15-19.
9. Dinh TP, Freund TF, Piomelli D (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121: 149-158.
10. Dinh TP, Kathuria S, Piomelli D (2004). RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66: 1260-1264.
11. Draper NR, Smith H (1998). Applied Regression Analysis. Wiley: New York.
12. 35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12: 2079-2086.
13. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92: 3376-3380.
14. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR (2000). Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 15: 510-521.
15. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
16. 1 receptors. Eur J Pharmacol 307: 331-338.
17. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997). Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61: PL191-PL197.
18. Ghilardi JR, Svensson CI, Rogers SD, Yaksh TL, Mantyh PW (2004). Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia. J Neurosci 24: 2727-2732.
19. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57: 1045-1050.
20. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422: 69-73.
21. 2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339: 53-61.
22. Guindon J, Beaulieu P (2006). Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50: 814-823.
23. Guindon J, LoVerme J, De Lean A, Piomelli D, Beaulieu P (2006a). Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol 550: 68-77.
24. Guindon J, De Léan A, Beaulieu P (2006b). Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121: 85-93.
25. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
26. Hohmann AG (2002). Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121: 173-190.
27. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
28. Hohmann AG, Herkenham M (1999). Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92: 1171-1175.
29. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
30. Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR et al. (1997). AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol 321: 1-3.
31. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
32. 2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42.
33. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76: 189-199.
34. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
35. Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P et al. (1999). Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem 42: 1682.
36. Lee M, Yang KH, Kaminski NE (1995). Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275: 529-536.
37. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302: 73-79.
38. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
39. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G et al. (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8: 1139-1141.
40. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
41. th annual symposium on the cannabinoids Paestum, Italy.
42. 2 cannabinoid receptors. Chem Phys Lipids 121: 191-200.
43. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445.
44. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
45. McCall WD, Tanner KD, Levine JD (1996). Formalin induces biphasic activity in C-fibers in the rat. Neurosci Lett 208: 45-48.
46. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
47. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
48. 2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757.
49. Nackley AG, Suplita II RL, Hohmann AG (2003b). A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117: 659-670.
50. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG (2004). Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92: 3562-3574.
51. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995). AM630, a competitive cannabinoid receptor antagonist. Life Sci 56: 1949-1955.
52. Petricevic M, Wanek K, Denko CW (1978). A new mechanical method for measuring rat paw edema. Pharmacology 16: 153-158.
53. Pitcher GM, Henry JL (2002). Second phase of formalin-induced excitation of spinal dorsal horn neurons in spinalized rats is reversed by sciatic nerve block. Eur J Neurosci 15: 1509-1515.
54. Puig S, Sorkin LS (1996). Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain 64: 345-355.
55. 2 cannabinoid receptors. Anesthesiology 99: 955-960.
56. Rice AS, Farquhar-Smith WP, Nagy I (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66: 243-256.
57. Richardson JD (2000). Cannabinoids modulate pain by multiple mechanisms of actions. J Pain 1: 2-14.
58. Richardson JD, Kilo S, Hargreaves KM (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111-119.
59. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
60. Saario SM, Savinainen JR, Laitinen JT, Jarvinen T, Niemi R (2004). Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67: 1381-1387.
61. Sugiura T, Kodaka T, Kondo S, Tonegawa T, Nakane S, Kishimoto S et al. (1996). 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 229: 58-64.
62. 2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 7: 605-612.
63. Tjölsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992). The formalin test: an evaluation of the method. Pain 51: 5-17.
64. 2 receptors. Science 310: 329-332.
65. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2005). Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132: 1093-1102.
66. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006). Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83: 1310-1322.
67. Watson GS, Sufka KJ, Coderre TJ (1997). Optimal scoring strategies and weights for the formalin test in rats. Pain 70: 53-58.
68. Winer BJ (1971). Statistical Principles in Experimental Design. McGraw-Hill: New York.
69. 1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785.